MASI · Masimo Corp
Market Cap
$9.42B
Shares
52.37M
No Price Data
No daily price data is available for this stock yet. Data syncs automatically from Yahoo Finance.
Up next
FQ3-27 quarter ends
~Oct 2, 2026
Est
filed May 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Limited
Momentum
Limited
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Limited
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
Not enough data for a confident read.
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
-100% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.69% of float · ▼ -6.1% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
2 holders — near 3-yr low, contrarian setup
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
76%
expanding
EPS growth
+50%
Y/Y
Free cash flow
$198.4M
Balance sheet
$372.0M
net debt
Quant / Vol
risk profile
Not enough data for a confident read.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jan 10, 2024
this year
Healthcare margin
62.7%
Q4
Healthcare margin
63%
Prior guidance
period ended
· from the 8-K filed Jan 12, 2026
Revenue
· fourth quarter 2025
$411M
Non-GAAP earnings per diluted share
· fourth quarter 2025
at least $1.54
Revenue
· full-year 2025
$1.52B
Non-GAAP earnings per diluted share
· full-year 2025
at least $5.55
Guided vs delivered
· last 2 settled
Consolidated revenue
fourth quarter of 2024
guided $581M – $611M
$368.4M
Miss −38.2%
Consolidated revenue
full-year 2024
guided $2.08B – $2.11B
$1.4B
Miss −33.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Shipments of noninvasive technology boards and instruments | 270K | Full-Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MASI
this stock
Masimo Corp
|
$9.42B | — | +8.3% | — | 6.7% |
|
ABT
Abbott Laboratories
|
$194.07B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$133.18B | -3.5% | +11.2% | 36.0 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Key facts
CIK
937556
CUSIP
574795100
13F (30d)
11 filings
10 filers
Visit website
Investor relations